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Abstract
Anti-citrullinated peptide/protein antibodies (ACPAs) are the most specific serological bio-
markers for rheumatoid arthritis (RA). They have both diagnostic and prognostic value, and
are related to more aggressive joint disease in RA. However, a single biomarker cannot dif-
ferentiate RA subtypes. So, simultaneous analysis of target citrullinated peptides, using a
multiplex array based on chimeric peptides composed of several domains of human pro-
teins, could be useful. In this work, eight chimeric peptides and the corresponding native
arginine-containing control peptides were obtained by solid-phase peptide synthesis. The
study included RA and psoriatic arthritis (PsA) patients attending the Rheumatology Unit of
the Hospital Clinic in Barcelona, as well as healthy blood donors (BD) at the same hospital.
Our main aim was to explore the diagnostic value of the novel multiplex array compared to a
commercial ELISA-based ACPA assay in a serum-saving way. Using the combination of the
eight chimeric peptide antigens in the multiplex array, 61.4% of the RA cohort were positive
for 3 or more peptides; while, the healthy BD and PsA cohorts did not show any reactivity
with the tested peptides. These results indicate that we have developed a highly specific
multiplex assay based of chimeric citrullinated peptides derived from filaggrin, fibrin, vimen-
tin and human enolase proteins for the detection of ACPAs in a serum-saving way.
Introduction
Rheumatoid arthritis (RA) is a chronic and incapacitating inflammatory disease of the joints
which is estimated to affect 0.5%-1% of the population worldwide. Long-lasting and the more
severe cases can also develop into a systemic disease and have extra-articular effects [1,2]. As
symptoms do not always appear in the early stages of the disease, there is a clear need to
improve both the precision of specific tests for its diagnosis, and its early differentiation from
other rheumatic diseases that affect the articulations and connective tissue. This is especially so
in the case of patients with a poor prognosis or those in the early developmental stages of the
disease.
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In recent years, several posttranslational modifications have been reported in the context of
RA, such as citrullination and carbamylation of proteins as well as proteins containing MAA
(malondialdehyde-acetaldehyde) adducts which co-localize in the inflamed synovial tissue of
RA patients [3,4]. However, the highest specificity for the diagnosis of RA is achieved via anal-
ysis of deiminated peptides or proteins, i.e., epitopes containing citrulline residues [5]. Anti-
citrullinated peptide/protein antibodies (ACPAs) are the most specific serological biomarkers
for RA. They have both diagnostic and prognostic value, and are related to a more aggressive
joint disease in RA. However, a single biomarker cannot differentiate RA subtypes, so simulta-
neous analysis of the target citrullinated peptides, incorporated into a multiplex test, would
facilitate the biological fingerprinting of autoantibodies in serum that would allow us to iden-
tify subgroups of patients with specific clinical characteristics. These may include different
prognoses; and those who either respond well to, or suffer negative effects from, certain thera-
peutic interventions.
Within this context, in previous work we already mapped the epitope anti-citrullinated
fibrin and vimentin antibody responses using synthetic peptides obtained by solid-phase pep-
tide synthesis, with the aim of improving the balance between sensitivity and specificity. The
peptides selected were covalently combined to render several chimeric peptides bearing fibrin,
vimentin and filaggrin domains [6,7]. We have demonstrated that the presence of different
peptide sequences within the same molecule can result in synergistic effects compared to the
monomeric peptides or the corresponding physical mixture of them [6,8,9]. Our previous
results have shown that there are potential applications of RA diagnostic systems based on chi-
meric peptides composed of several citrullinated domains of human proteins. Moreover, those
findings imply that more than one serological test that combine these target peptides in a sin-
gle analysis is required to classify patients based on the presence or absence of ACPAs.
In this work, we now aim to analyze eight chimeric citrullinated peptides derived from dif-
ferent proteins present in rheumatoid synovial fluid simultaneously, incorporating them into a
multiplex test. This will thereby allow us to explore the diagnostic value of the multiplex array
compared to an ELISA-based commercial ACPA assay in a serum-saving way. These results
could have far-reaching practical implications in the future for establishing whether the multi-
plex system adds power to current RA tests.
Materials and methods
The work was approved by the Ethics Committees of the Consejo Superior de Investigaciones
Científicas (CSIC), Madrid, Spain, and of the Hospital Clinic, Barcelona, Spain. All methods
were performed in accordance with the relevant IQAC-CSIC guidelines and regulations. Writ-
ten consent was obtained from all participants and suitably informed.
Chimeric peptides
The eight chimeric peptides shown in Fig 1 were manually synthesized as C-terminal carboxa-
mides in polypropylene syringes, each fitted with a polyethylene porous disk. 9-fluorenyl-
methoxycarbonyl (Fmoc)-protected amino acids (3 equiv) and 2-(1H-7-azabenzotriazole-
1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate methanaminium (HATU) (3 equiv)
were added sequentially to the resin in dimethylformamide (DMF) (3 mL) followed by diiso-
propylethylamine (DIPEA) (6 equiv).
The mixture was allowed to react, with intermittent manual stirring, for 30 min. The sol-
vent was removed by filtration, and the resin was washed with DMF (5 × 30 s). The extent of
coupling was checked by applying the Kaiser colorimetric assay or the De Clercq test. The
Fmoc group was removed by treating the resin with 20% piperidine in DMF (3–4 mL/g resin,
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Fig 1. Primary structure of chimeric citrullinated peptides derived from fibrin, filaggrin, vimentin and enolase
proteins.
https://doi.org/10.1371/journal.pone.0215927.g001
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2 × 10 min). Peptide elongation continued by coupling the second and subsequent amino
acids using the same procedure. The peptides were cleaved from the resin by means of treat-
ment with 95% trifluroacetic acid (TFA) in the presence of scavengers: 2% H2O, 2% 1,2-etha-
nedithiol (EDT) and 1% triisopropylsilane (TIS) for 3 h. In order to synthesize the cyclic
chimeric peptide, 2 serine residues in the linear peptide were substituted for 2 cysteines. After
peptide cleavage, the peptide was dissolved in acetic acid (AcOH)/H2O (1:1, 3 mg/mL) under
N2, then HCl (1 M, 0.1 mL/mg) followed by I2 (20 equiv/acetamidomethyl, Acm) were added
to the solution. After 4 h, the I2 was quenched by adding 1 M ascorbic acid drop-wise until the
mixture became colorless and then it was concentrated by evaporation under reduced pressure
to approximately one third of the original volume. The final product was purified by semipre-
parative HPLC in a Kromasil C-18 column (Tecknokroma, 5 μm, 25 x 1 cm) with a linear gra-
dient of 100%-75% A in B over 30 min, at a flow rate of 4 mL/min, using 0.05% TFA in water
(A) and 0.05% TFA in acetonitrile (B) as the eluting system. The purified chimeric peptides
(purity greater than 95%) were characterized by analytical ultra-performance liquid chroma-
tography (UPLC) and electrospray ionization mass spectrometry (ES-MS).
Serum specimens
Patients who fulfilled revised ACR/EULAR 2010 criteria for the classification of RA were
enrolled in this study. They were all outpatients attending the Rheumatology Unit of the Hos-
pital Clinic in Barcelona. Serum samples used as negative controls were obtained from blood
donors at the same hospital. Sera were previously tested in duplicate for the presence of anti-
CCP3 (Immunoscan RA; Eurodiagnostica, distributed by Diasorin, Madrid, Spain) and anti-
CFFCPs, anti-CVFCP and anti-CFVcCP as previously described [6, 7]. Patients with psoriatic
arthritis (PsA) meeting CASPAR criteria [10] were included as an inflammatory control
group.
ELISA assays
Peptide sequences were coupled covalently to ELISA microplates (Costar Corp., DNA-bind N-
oxysuccinimide surface, Cambridge, MA, USA) as previously described [6, 7]. Briefly, the pep-
tides were diluted to 10 μg/mL in 0.05 M carbonate/bicarbonate buffer (pH 9.6). Then, 100 μL
of the peptide solution was added to each well of microplates and incubated overnight at 4˚C.
Each plate contained control wells that included all reagents except the serum sample in order
to estimate the background reading, together with control wells that included all reagents
except the peptide to evaluate non-specific serum reactions. For blank controls, wells were
coupled with 2 μg BSA/well. After incubation, the plates were blocked with 2% bovine serum
albumin (BSA) in 0.05 M carbonate/bicarbonate buffer (pH 9.6) for 1 h at room temperature.
Sera were diluted 50-fold in RIA buffer (1% BSA, 350 mM NaCl, 10 mM Tris-HCl, pH 7.6, 1%
vol/vol Triton X-100, 0.5% wt/vol Na-deoxycholate, 0.1% SDS) supplemented with 10% fetal
bovine serum. Afterwards, 100 μL/well was added and incubated for 1.5 h at room tempera-
ture. After washing 6 times with phosphate-buffered saline (PBS)/0.05% Tween-20, we added
100 μL/well of anti-human IgG conjugated to peroxidase diluted 1:1000 in RIA buffer. After
incubation for 1 h at room temperature, the plates were washed 6 times with PBS/0.05%
Tween-20 and bound antibodies were detected with o-phenylenediamine dihydrochloride
(OPD, Sigma-Aldrich, St. Louis, MO, USA and 0.8 μL/mL 30% hydrogen peroxide. The plates
were incubated at room temperature for 30 min. The reaction was stopped with 50 μL of 2N
H2SO4 per well and absorbance values were measured at a wavelength of 492 nm. All the sera
were tested in duplicate. Control sera were also included to monitor inter- and intra-assay
variations.
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Microarray design
To perform microarray assays, the peptides were covalently immobilized (Miniarrayer BioO-
disseyTM CalligrapherTM, BioRad, CA, USA) on the slides via epoxide groups. The immuno-
assay procedure was carried out as described previously [11]. A secondary antibody anti-
human IgG labeled with Alexa Fluor 647 was used and the fluorescence of the spots was quan-
tified in a scanner (ScanArray GX Plus, Perkin Elmer). The microarray assay was then opti-
mized in two steps.
Firstly, the plates were blocked with 2% BSA in 0.05 M carbonate/bicarbonate buffer (pH
9.6) for 1 h at room temperature. Afterwards, serum samples (diluted 1:50) were analyzed for
the presence of ACPA-specific IgG working with three chimeric peptides (CFFCP1, CFFCP2
and CFFCP3) that were spotted in quintuplicate on: 1) glass slides coated with an epoxy group
or 2) Super NHS microarray substrate slides (ArrayIt, CA, USA). After 1.5 h of incubation at
room temperature in a humidity chamber, the slides were washed six times with PBS tween
buffer and the anti-human IgG labeled with Alexa Fluor 647 (dilution 1:250) was added and
incubated at room temperature for 1 h. Microarray fluorescence was read using excitation and
emission wavelengths of 633 and 647 nm, respectively. The Scan Array GX Plus software calcu-
lates intensity homogeneity (as a coefficient of within individual spots and intra-spot variabili-
ties) for all spots coated with the same peptide. In this first assay, the glass slides coated with
epoxy groups yielded better results.
Secondly, the same procedure as indicated above was carried out but diluting the peptides
in two types of buffer: 1) carbonate buffer pH 9.6 or 2) peptide printing buffer (ArrayIt, CA,
USA). The three peptides were spotted in quintuplicate on glass slides coated with an epoxy
group using 18 and 6 randomly selected RA and 6 BD samples respectively (24 was the maxi-
mum number of samples on a slide). Microarray slides spotted with peptides diluted in car-
bonate buffer showed better results than those in the commercial buffer. Consequently, the
final microarray assay that we performed with all the chimeric peptides was carried out in this
way. Nevertheless, in order to improve spot intensity, the peptides/serum incubation time was
increased to 2 h and also a lower dilution of anti-human IgG labeled with Alexa Fluor 647
(1:100) was used. The eight chimeric peptides were spotted in triplicate in the final assay. At
least two of the three spots should be accepted to obtain results. After this, sera that still ren-
dered a high coefficient of variation (CV) were discarded.
Statistical analysis
Cut-off values for homemade ELISA tests were selected according to receiver operating char-
acteristic (ROC) analysis, to give a specificity of 98% for RA versus healthy blood donors (BD).
In order to evaluate the diagnostic properties of the different peptides, sensitivity, specificity
and positive and negative predictive values (PPV and NPV) were calculated using the RA and
BD cohorts. Quantitative data were reported as means, standard deviations, medians and
interquartile ranges; absolute frequencies and percentages were used to describe qualitative
data.
The association between microarray and ELISA values was analyzed using the nonparamet-
ric Spearman rank correlation coefficient due to the nonsymmetric distributions of the data.
To compare percentages, the classical two-sample test of proportions was used. All p-values
were two sided and the significance level was established at α = 0.05. Comparison and analysis
of ROC curves and all other statistical analysis was performed using STATA 15.0 statistical
software [12].
Multiplex assay for RA diagnosis
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Results and discussion
As previously reported [6,7], the identification of novel citrullinated antigens that could sup-
plement or complement ACPA-based existing tests, is required. A challenging approach con-
sists of analyzing ACPA profiles using multiple citrullinated peptide antigens simultaneously.
In the present work, considering the increased antigenicity previously observed with multi-
meric peptides bearing different epitope peptide sequences within the same molecule, we
designed and synthesized three new chimeric peptides in the solid phase. They were composed
of citrullinated peptides derived from filaggrin (cyclic filaggrin peptide, constituting the CCP1
test), fibrin (617–631), vimentin (47–72) and enolase (CEP-1), and herein we refer to them as
chimeric fibrin/enolase citrullinated peptide (CFECP), chimeric vimentin/enolase citrullinated
peptide (CVECP) and chimeric enolase/filaggrin citrullinated peptide (CEFCP). The analytical
characterization of these three novel chimeric peptides using UPLC-MS is shown in the Sup-
plementary material (Figs A, B and C in S1 File) and the primary structure of all the chimeric
citrullinated peptides studied in the present work is shown in Fig 1. Firstly, a comparative
ELISA assay was performed in cohorts of 100 RA and 87 BD sera using CFECP, CVECP and
CEFCP as coating antigens; as was previously performed with the chimeric peptides CFFCP1,
CFFCP2, CFFCP3, CFVCP and CVFCP [6, 7]. The values of the area under the ROC curve
(RA vs BD) are shown in Fig 2: CEFCP: 0.78; CVECP: 0.71; CFECP: 0.78. Using cut-off values
that yield a specificity of 98.85% with respect to BD, the sensitivity of the ELISAs was 63% for
CEFCP, 37% for CVECP, and 56% for CFECP; with PPV > 97.4% in all three tests and NPV
between 57.7% and 69.9%.
Our results indicate that these new chimeric citrullinated peptides derived from human
proteins should be considered for inclusion in the design of a multiplex citrullinated peptide-
based array for the diagnosis of RA. In order to identify the best conditions for performing the
multiplex assays, optimization experiments were conducted as described in the Materials and
methods section above. We analyzed the diagnostic value of a multiplex array containing the
eight different citrullinated chimeric peptides and their arginine counterparts (to control for
citrulline specificity), which had previously been validated using another panel of RA sera and
the CFFCP antigens [11]. A subset of 70 healthy BDs from the cohort used for ELISA analysis
was used to establish the cut-off for each of the chimeric peptide antigens tested. To control
for specificity, we used a panel of 70 sera derived from patients affected by PsA, an inflamma-
tory disease with a clinical presentation that can simulate that of RA. First of all, the intra-assay
CV was calculated for all sample/peptide pairs. We clearly observed higher fluorescence inten-
sity response units (RUs) for the pairs of RA/citrullinated peptides than for the other pairs
studied (BD or PsA/citrullinated peptides or arginine control peptides, and RA/arginine con-
trol peptides). In agreement with this, low-level RU samples (BD and PsA) showed overall a
higher CV than high-level RU samples (RA). We therefore decided to exclude from the study
those sera where CV> 30% in low-level RU and those with CV> 25% in samples with high
intensity (Table A in S1 File). At least two spots in a triplicate had to be accepted to obtain
results. Several examples of a positive RA serum and negative sera (PsA and BD) are shown in
Fig 3.
The association between the measurements performed by microarray and ELISA was made
using uncorrected values. Comparison of the fluorescence intensities with the corresponding
optical density units yielded satisfactory Spearman’s rank correlation coefficients (ρS): values
between 0.70 and 0.83 (Fig D in S1 File). Moreover, the performance of each individual chime-
ric peptide in the multiplex system was compared with its performance in the ELISA assay. As
shown in the ROC curves obtained (Fig E in S1 File), at a level of specificity of 98%, the indi-
vidual chimeric peptides showed marked differences in sensitivity which also depended on
Multiplex assay for RA diagnosis
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whether the arginine control peptides were subtracted. In general, this correction improved
the sensitivity of the corresponding assay (increased the number of RA subjects that were posi-
tive), with the only exception of CFVCP, where the number of positive sera decreased (sensi-
tivity values decreased from 36.8% to 30.0%). For CFECP and CEFCP, the effect of subtraction
of citrulline control reactivity was null and did not affect the corresponding sensitivity values
(Table 1). So, we decided to work with corrected values to measure the sensitivity of the eight
chimeric citrullinated peptides in the multiplex array.
Table B in S1 File shows the individual reactivity of each citrullinated chimeric peptide for
the RA, healthy BD and PsA cohorts. The results indicate that PsA patients and BD controls
behave similarly, and clearly demonstrate very low reactivity compared to RA patients. To
compare results of the combination of the eight chimeric citrullinated peptides (patterns) and
the CCP3 commercial test for the RA cohort, a linear regression model was fitted (Fig 4).
The model was statistically significant (p = 0.0025) and the coefficient of determination (R-
squared) indicates that 75.67% of the variability in CCP3 values is explained by the number of
positive citrullinated peptides. Table 1 shows the individual performance of the eight chimeric
citrullinated peptides included in the study, in comparison with the commercial CCP3 test, in
the RA cohort. As shown in Table 2, three of these peptide sequences behaved significantly dis-
cordantly with the commercial test (CFFCP1, CFFPCP2 and CFVCP).
Consequently, next we analyzed how the multiplex system works in comparison to CCP3,
with regard to the peptides we considered for inclusion in the array. Firstly, the analysis was
carried with all the (eight) peptides and considering multiplex positive to be when three or
more peptides were positive. In this case, the following values were obtained: 76.4% sensitivity,
90.9% specificity. When the same analysis conditions were used, but excluding CFFCP1,
CFFPCP2 and CFVCP (five peptides were included in the analysis), the results were: 64.8%
sensitivity, 90.9% specificity. Then, taking into account that CFFCP1 and CFFCP2 behave
identically and although the pattern of citrullination in the primary structure of the three
CFFCPs is different, they are composed of the same domains as filaggrin and fibrin proteins,
we decided to perform the analysis excluding CFFCP1 and CFFCP2 and maintaining CFVCP.
In this last case, the multiplex array contained six peptides and we considered it to be positive
when three or more peptides were positive, the corresponding values of sensitivity and
Fig 2. ROC curve analysis from ELISA results with chimeric fibrin-filaggrin-vimentin-enolase citrullinated
peptides (CEFCP, CVECP and CFECP) in the cohort of patients with RA (n = 100) and of blood donors (n = 87).
https://doi.org/10.1371/journal.pone.0215927.g002
Fig 3. Graphic representation of the fluorescence intensities obtained from (a) an ACPA-positive RA serum, (b) an ACPA-negative control serum and (c) an ACPA-
negative PsA serum.
https://doi.org/10.1371/journal.pone.0215927.g003
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Table 1. Performance of the eight citrullinated peptides studied and their comparison with the commercial ELISA-based CCP3 test.
Peptide % of RA sera reacting at 98.0% specificity % of the same RA sera reacting to CCP3 p
CFFCP1 20/34 (58.8%) 30/34 (88.2%) 0.006�
CFFCP2 23/34 (67.7%) 31/34 (91.2%) 0.016�
CFFCP3 35/44 (79.6%) 38/44 (86.4%) 0.395
CFECP 30/38 (79.0%) 33/38 (86.8%) 0.361
CFVCP 21/57 (36.8%) 49/57 (86.0%) 0.000�
CVECP 39/46 (84.8%) 39/46 (84.8%) 1.000
CEFCP 38/45 (84.4%) 40/45 (88.9%) 0.535
CVFCP 42/52 (80.8%) 44/52 (84.6%) 0.604
p: two-sample test of proportions p-value
� p < 0.05
https://doi.org/10.1371/journal.pone.0215927.t001
Fig 4. Association between mean CCP3 values and the number of positive citrullinated peptides in the multiplex system. Results of the fitted linear regression
model.
https://doi.org/10.1371/journal.pone.0215927.g004
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specificity were: 72.2% and 90.9%, respectively. Finally and similarly to what is previously
reported in the literature [13, 14] when array positivity is defined as being positive for more
than two or more than one peptide, results were poorly RA-specific. This confirms the impor-
tance of critical selection of citrullinated peptides. In view of all these results, summarized in
Table 2, we performed the subsequent analysis using the whole panel of eight peptides, as
shown in Fig 1.
Fig 5 shows the relative frequency of ACPA positives in the three cohorts (RA and PsA
patients; and healthy BD) for the combination of the eight chimeric peptide antigens. As
shown, the proportion of RA patients that were positive to 3 or more peptides was 61.4%;
while the healthy BD and PsA cohorts showed 0% of these 3-fold ACPA positives.
When array positivity was defined as more than one chimeric peptide antigen being posi-
tive, positivity in the RA cohort was 81.4%; while in the two control cohorts, it was 7.1% and
8.6% for BDs and PsA patients respectively. These results demonstrate sensitivity values com-
parable to those reported by others [15, 16]; while we observed 100% specificity for RA diagno-
sis when positivity was considered with 3 or more peptides being positive. When comparing
with the commercial CCP3 test, discordant results were obtained in 21% of the RA sera studied
(13 of 66 were CCP3 positive and multiplex negative; and 1 of 66 resulted CCP3 negative and
multiplex positive). These findings reflect the differences that exist in the peptide repertoire in
the two platforms and reinforce both the broad heterogeneity of ACPAs and the increasing
Table 2. Sensitivity and specificity analysis of the multiplex assay compared to the commercial ELISA-based CCP3 test, regarding peptide biomarker selection.
Multiplex: all peptide biomarkers (8)
2+ 3+
CCP3 - + CCP3 - +
- 7 4 11 - 10 1 11
+ 8 47 55 + 13 42 55
15 51 66 23 43 66
Sensitivity 85,50% Sensitivity 76,40%
Specificity 63,60% Specificity 90,90%
Multiplex: 5 peptide biomarkersa
2+ 3+
CCP3 - + CCP3 - +
- 8 3 11 - 10 1 11
+ 11 43 54 + 19 35 54
19 46 65 29 36 65
Sensitivity 79,60% Sensitivity 64,80%
Specificity 72,70% Specificity 90,90%
Multiplex: 6 peptide biomarkersb
2+ 3+
CCP3 - + CCP3 - +
- 8 3 11 - 10 1 11
+ 10 44 54 + 15 39 54
18 47 65 25 40 65
Sensitivity 81,50% Sensitivity 72,20%
Specificity 72,70% Specificity 90,90%
CCP3: < 20 = —vs� 20 = +
a CFFCP1, CFFCP2 and CFVCP excluded
b CFFCP1 and CFFCP2 excluded.
https://doi.org/10.1371/journal.pone.0215927.t002
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number of citrullinated proteins or peptides that present different reactivity patterns with RA
sera [17]. Moreover, a great number of studies have reported non-specific responses of com-
mercial RA tests [18–20] due to the fact that they never routinely perform a parallel control
with the peptides containing native arginine, instead of citrulline. However, our multiplex
array easily allows us to perform this control and thus the results reported here for ACPA reac-
tivity are strictly citrulline specific.
Conclusions
Here, we have develop a novel multiplex platform composed of eight chimeric citrullinated
peptides derived from human proteins that abound in rheumatoid synovial, and we have eval-
uated its suitability to detect anti-citrullinated peptide/protein antibodies (ACPAs) in serum
samples of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients, as well as in healthy
blood donors. Our results demonstrate that the platform has a high specificity for ACPA detec-
tion, especially taking into account that the control group consisted of patients affected by
Fig 5. Patterns of reactivities of the eight citrulline peptides in RA patients, healthy BDs and PsA patients.
https://doi.org/10.1371/journal.pone.0215927.g005
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PsA, an inflammatory disease whose clinical presentation can simulate that of RA. When com-
paring with the commercial ELISA-based test (CCP3), it is true that ACPA reactivity was only
detected by the multiplex array in one CCP3-negative RA serum sample. However, this in-
house multiplex system allowed us to control for background reactivity to arginine and worked
in a serum-saving way, compared to CCP3. In conclusion, a highly citrulline-specific multiplex
assay based on chimeric citrullinated peptides derived from filaggrin, fibrin, vimentin and
human enolase proteins for the detection of ACPAs has been developed herein. In order to
improve sensitivity and expand future use in RA diagnosis, peptides bearing other non-protei-
nogenic amino acids could be designed, synthesized and incorporated into the platform as
novel antigenic substrates for further development of the multiplex system.
Supporting information
S1 File. UPLC-MS characterization of CFECP (Fig A), CEFCP (Fig B) and CVECP (Fig C).
Relationship between fluorescence intensities (microarray) (RU) and the corresponding opti-
cal density units (ELISA) (OD) for RA patients (Fig D). ROC curves analysis from microarray
results (Fig E). Number of discarded sera in RA, BD and PsA cohorts (Table A). Reactivity of
RA, BD and PsA cohorts to each citrullinated peptide (Table B).
(DOCX)
Author Contributions
Conceptualization: Isabel Haro.
Data curation: Marı´a Jose´ Bleda.
Formal analysis: Marı´a Jose´ Go´mara, Marı´a Jose´ Bleda.
Funding acquisition: Isabel Haro.
Investigation: Marı´a Jose´ Go´mara, Raimon Sanmartı´.
Methodology: Cristina Garcı´a-Moreno.
Software: Marı´a Jose´ Bleda.
Supervision: Raimon Sanmartı´, Isabel Haro.
Validation: Raimon Sanmartı´.
Writing – original draft: Isabel Haro.
Writing – review & editing: Isabel Haro.
References
1. Klareskog L, Catrina A, Paget S. Rheumatoid Arthritis. Lancet 2009; 373: 659–72. https://doi.org/10.
1016/S0140-6736(09)60008-8 PMID: 19157532
2. Mclnnes IB and Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205–19.
https://doi.org/10.1056/NEJMra1004965 PMID: 22150039
3. Trouw LA, Rispens T, Toes REM. Beyond citrullination: other post-translational protein modifications in
rheumatoid arthritis. Nat Rev Rheumatol 2017; 13: 331–9. https://doi.org/10.1038/nrrheum.2017.15
PMID: 28275265
4. Thiele GM, Duryee MJ, Anderson DR, Klassen LW, Mohring SM, Young KA et al. Malondialdehyde-
acetaldehyde adducts and anti-malondialdehyde-acetaldehyde antibodies in rheumatoid arthritis.
Arthritis Rheumatol 2015; 67: 645–55. https://doi.org/10.1002/art.38969 PMID: 25417811
5. Go´mara MJ and Haro I. Citrullinated peptides in the diagnosis of Rheumatoid Arthritis. Curr Top Med
Chem, 2013; 13: 743–51. PMID: 23574523
Multiplex assay for RA diagnosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0215927 May 2, 2019 12 / 13
6. Pe´rez ML, Go´mara MJ, Ercilla G, Sanmartı´ R, Haro I. Antibodies to citrullinated human fibrinogen syn-
thetic peptides in diagnosing rheumatoid arthritis J Med Chem 2007; 50: 3573–84. https://doi.org/10.
1021/jm0701932 PMID: 17585853
7. Malakoutikhah M, Go´mara MJ, Go´mez-Puerta JA, Sanmartı´ R, Haro I. The use of chimeric vimentin
citrullinated peptides for the diagnosis of rheumatoid arthritis. J Med Chem 2011; 54: 7486–92. https://
doi.org/10.1021/jm200563u PMID: 21981664
8. Pe´rez T, Ercilla G, Chan W, Haro I. Antigenicity of chimeric and cyclic synthetic peptides based on non-
structural NS4 and NS5 proteins of GBV-C/HGV. J Pep Sci, 2006; 12: 267–78.
9. Go´mara MJ, Riedemann S, Vega I, Ibarra H, Ercilla G, Haro I. Use of linear and multiple antigenic pep-
tides to immunodiagnosis of acute hepatitis A virus infection. J Immunol Met 2000; 234: 23–34.
10. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classifi-
cation criteria for psoriatic arthritis: development of new criteria from a large international study Arthr.
Rheum. 2006, 54: 2665
11. Gomara MJ, Rodrı´guez J, Bleda MJ, Salvador JP, Sanmartı´ R, Haro I. Comparative study of the diag-
nostic and prognostic value of antibodies against chimeric citrullinated synthetic peptides and CCP3 /
CCP3.1 assays. Clin Chem Lab Med 2018; 56(2): 285–93. https://doi.org/10.1515/cclm-2017-0264
PMID: 28850543
12. StataCorp. 2017. Stata: Release 15. Statistical Software. College Station, TX: StataCorp LLC
13. Wagner CA, Sokolove J, Lahey LJ, Bengtsson C, Saevarsdottir S, Alfredsson L et al. Identification of
anticitrullinated protein antibody reactivities in a subset of anti-CCP-negative rheumatoid arthritis: asso-
ciation with cigarette smoking and HLA-DRB1 “shared epitope” alleles. Ann Rheum Dis 2015; 74: 579–
86. https://doi.org/10.1136/annrheumdis-2013-203915 PMID: 24297382
14. Van Heemst J, Trouw LA, Nogueira L, van Steenbergen HW, van der Helm-van Mil AHM, Allaart CF
et al. An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis
setting. Arthr Res Ther 2015; 17: 276–86.
15. Hansson M, Mathsson L, Schlederer T, Israelsson L, Matsson P, Nogueira L et al. Validation of a multi-
plex chip-based assay for the detection of autoantibodies against citrullinated peptides. Arthr Res Ther
2012; 14: R201
16. Ro¨nnelid J, Hansson M, Mathsson-Alm L, Cornillet M, Reed E, Jakobsson PJ et al. Anticitrullinated pro-
tein/peptide antibody multiplexing defines an extended group of ACPA-positive rheumatoid arthritis
patients with distinct genetic and environmental determinants. Ann Rheum Dis 2017; https://doi.org/10.
1136/annrheumdis-2017-211782 PMID: 29070529
17. Uysal H, Nandakumar KS, Kessel C et al. Antibodies to citrullinated proteins molecular interactions and
arthritogenicity. Immunol Rev 2010; 233: 9–33. https://doi.org/10.1111/j.0105-2896.2009.00853.x
PMID: 20192990
18. Kakumanu P, Yamagata H, Sobel ES, et al. Patients with pulmonary tuberculosis are frequently positive
for anti-cyclic citrullinated peptide antibodies, but their sera also react with unmodified arginine-contain-
ing peptide. Arthritis Rheum 2008; 58: 1576–81. https://doi.org/10.1002/art.23514 PMID: 18512773
19. Vannini A, Cheung K, Fusconi M, et al. Anti-cyclic citrullinated peptide positivity in non-rheumatoid
arthritis disease samples: citrulline-dependent or not? Ann Rheum Dis 2007; 66: 511–6. https://doi.org/
10.1136/ard.2006.058933 PMID: 16984940
20. Ahlin E, Elshafie AI, Nur MA, et al. Anti-citrullinated peptide antibodies in Sudanese patients with Leish-
mania donovani infection exhibit reactivity not dependent on citrullination. Scan J Immunol 2015; 81:
201–8.
Multiplex assay for RA diagnosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0215927 May 2, 2019 13 / 13
